MedTrace Logo

A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors

NCT06716619 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-03-26

No results posted yet for this study

Summary

A Phase I clinical trial of the safety and tolerability of tumor-associated lymph node T cell injection in patients with advanced malignant solid tumors, including but not limited to melanoma, head and neck tumors, cervical cancer, and non-small cell lung cancer.

Conditions

  • Tumor Associated Lymph Node T Cell
  • Advanced Solid Tumor
  • Immunotherapy
  • Serplulimab Injection

Interventions

BIOLOGICAL

Tumor Associated Lymph node T cell

At least one lymph sample is resected from each participant, then it is separated and cultured ex vivo to expand the population of Tumor Associated Lymph node T cells . After lymphodepletion, patients are infused with TAL-T.

DRUG

Serplulimab Injection

Srulizumab injection was given intravenous infusion both before and after the TAL-T cells infusion.

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • Guangzhou FineImmune Biotechnology Co., LTD.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-13
Primary Completion
2026-12-19
Completion
2027-12-19

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06716619 on ClinicalTrials.gov